Santaris Pharma

Last updated
Santaris Pharma A/S
Industry
Founded2003
FateAcquired by Roche Pharmaceuticals
Headquarters Copenhagen, Denmark
Products RNA-targeted medicines, Locked nucleic acid (LNA) based drugs

Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. [1] The company also had a branch in San Diego, California that opened in 2009. [2] Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine. [3]

Contents

Santaris had gained intellectual property rights to the therapeutic applications of locked nucleic acid (LNA) technology. These rights included ownership of several patents, mostly with the chemistry and manufacturing of therapeutic drugs. With its LNA technology, Santaris developed drugs for the treatment of cancers and tumours using microRNA and mRNA. Its research focused on infectious diseases and metabolic disorders. The company also worked on collaborations with other pharmaceutical companies to develop drugs that could treat cancers and rare genetic disorders, among other things. [3]

In August 2014, Santaris was acquired by Roche for $450 million. As a result, the Copenhagen site was renamed the Roche Innovation Center Copenhagen (RICC). [4] RICC houses Roche's RNA Molecule Research, which is part of Roche Pharma Research and Early Development. [5] In 2023, it was closed due to a decision to move research to Basel, Switzerland where Roche is headquartered. [6] The former employees of the RICC were offered new jobs at the Danish pharmaceutical company Novo Nordisk. [7]

Locked Nucleic Acid (LNA) drug platform

Santaris developed drugs based on Locked nucleic acid (LNA) to facilitate the identification and design of potential drug candidates. LNA oligonucleotides were engineered by Santaris as antisense therapeutic agents, designed to complement specific mRNA and microRNA sequences. This interaction leads to the formation of double-stranded RNA, preventing translation. Notably, LNA oligonucleotides are shorter than other antisense drugs, granting them greater target affinity and potency compared to regular RNA oligonucleotides.

One of the distinctive qualities of LNA drugs is their resistance to endonuclease activity, which contributes to their durability. Moreover, LNA drugs possess other advantageous attributes in comparison to other therapeutic agents: they can be administered without the need for complex drug delivery methods, their production is scalable and cost-effective, they are well-tolerated.[ verification needed ] These factors collectively define LNA-based drugs as innovative therapeutic agents. [8] [9] [3]

Drug candidates

Cancer drug candidates

In 2009, Santaris announced that two LNA based drugs EZN-3042, and EZN-2968 would be entering clinical trials. [10] EZN-2968 is an inhibitor of a transcription factor, specificially HIF-1 alpha, which is involved in cells ability to undergo angiogenesis and other processes needed for cell survival. EZN-3042 is also an inhibitor, which acts against Survivin. Santaris partnered with Enzon Pharmaceuticals, [11] for the development of both drug candidates.

Hyperlipidemia

SPC-4955 was a drug intended for the treatment of high cholesterol. SPC-4955 inhibits the protein that is necessary for the formation of plasma LDL cholesterol particles. This has the potential to be used as a treatment for patients with hyperlipidemia. [12] SPC-5001 which targets PCSK9 program also has the potential to treat patients with hyperlipidemia. It inhibits the protein that controls the number of receptors responsible for removing LDL cholesterol particles from the blood. [12]

As of 2022, clinical trials on SPC-4955 have been discontinued by Roche. [13]

Hepatitis C

Santaris developed a microRNA targeting drug for hepatitis C (HCV), miravirsen (SPC3649), [14] which entered Phase II clinical trials in 2010. [15] The drug targets miR-122, a host factor necessary for viral replication of the hepatitis C virus in host liver cells; because miravirsen targets a host factor rather than the virus itself, there are no indications of the virus developing resistance. [16] [ citation needed ] The U.S. Food and Drug Administration approved a multiple dosing study, by injection, to treatment-naive patients for phase II testing. [15]

Rare genetic disorders

Santaris had a collaboration with Shire to discover and develop new RNA-based medicines to treat rare genetic disorders. [17]

Collaborations

Santaris partnered with several pharmaceutical companies that wanted to develop LNA oligonucleotides for mRNA and microRNA targets. Pfizer and Santaris entered a collaboration pact in 2009, which was expanded in 2011. [18] It also had a partnership with Enzon for cancer drug targets, [11] Shire for lead candidates of five rare, undisclosed genetic disorders, [17] miRagen to develop treatments targeting microRNAs associated with cardiovascular disease, [19] and GlaxoSmithKline for RNA-targeted medication. [20]

Timeline

Awards

Litigation

In 2010, Exiqon completed its litigation against Santaris for the supply of LNA. The court determined that both companies may supply the product for research and development of pharmaceutical products. Exiqon was made to pay partial costs to Santaris of DKK 2 million within two weeks. [33]

Isis Pharmaceuticals filed a patent infringement lawsuit against Santaris Pharma A/S in the United States District Court for the Southern District of California in September 2011. Isis's infringement suit against Santaris is based upon Santaris's activities providing antisense drugs and antisense drug discovery services to several pharmaceutical companies. [34]

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. Several ASOs have been approved in the United States, the European Union, and elsewhere.

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

Takeda Oncology is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

<span class="mw-page-title-main">Mipomersen</span> Drug used to treat genetic hypercholesterolemia

Mipomersen is a drug used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of liver damage from this drug and it can only be prescribed in the context of a risk management plan.

Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Arbutus Biopharma</span> Canadian Bio Tech Company

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

<span class="mw-page-title-main">Ionis Pharmaceuticals</span> Biotechnology company

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.

<span class="mw-page-title-main">Miravirsen</span> Medication

Miravirsen is an experimental drug for the treatment of hepatitis C, being developed by Santaris Pharma. As of 2017 it was in Phase II clinical trials.

Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy.

<span class="mw-page-title-main">Gregory L. Verdine</span> American chemical biologist

Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.

RNA therapeutics are a new class of medications based on ribonucleic acid (RNA). Research has been working on clinical use since the 1990s, with significant success in cancer therapy in the early 2010s. In 2020 and 2021, mRNA vaccines have been developed globally for use in combating the coronavirus disease. The Pfizer–BioNTech COVID-19 vaccine was the first mRNA vaccine approved by a medicines regulator, followed by the Moderna COVID-19 vaccine, and others.

<span class="mw-page-title-main">Ultragenyx</span> American biopharmaceutical company

Ultragenyx is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.

Gapmers are short DNA antisense oligonucleotide structures with RNA-like segments on both sides of the sequence. These linear pieces of genetic information are designed to hybridize to a target piece of RNA and silence the gene through the induction of RNase H cleavage. Binding of the gapmer to the target has a higher affinity due to the modified RNA flanking regions, as well as resistance to degradation by nucleases. Gapmers are currently being developed as therapeutics for a variety of cancers, viruses, and other chronic genetic disorders.

References

  1. 1 2 3 "Santaris Pharma - 2008 Fierce 15". Fierce Biotech. June 2008.
  2. 1 2 "MicroRNA Drug Developer Santaris Establishes Toehold in San Diego With Isis Veteran". Xconomy. September 16, 2009. Archived from the original on 2021-05-12.
  3. 1 2 3 4 "Developing LNA technology for new-generation cancer drugs" (PDF). SP2 Magazine. March 2006.
  4. ↑ "Forbion Announces Sale of Portfolio Company, Santaris Pharma, to Roche for up to $450m". www.businesswire.com. 2014-08-04. Retrieved 2022-03-05.
  5. ↑ "Roche | Pharma R&D - Copenhagen, Denmark". www.roche-dot-com-staging.cwp.roche.com. Retrieved 2024-05-12.
  6. ↑ "Roche to close Danish research center with 60 workers". medwatch.com. 2022-10-26. Archived from the original on 2023-02-15. Retrieved 2024-05-31.
  7. ↑ "Roche opens Novo Nordisk career path for laid-off employees". medwatch.com. 2022-12-19. Retrieved 2024-05-31.
  8. 1 2 3 4 Weiss, B.; Davidkova, G.; Zhou, L. W. (March 1999). "Antisense RNA gene therapy for studying and modulating biological processes". Cellular and Molecular Life Sciences. 55 (3): 334–358. doi:10.1007/s000180050296. ISSN   1420-682X. PMC   11146801 . PMID   10228554.
  9. ↑ Weiss B., Davidkova G., Zhou L-W. (1999). "Antisense RNA gene therapy for studying and modulating biological processes". Cell. Mol. Life Sci. 55 (3): 334–358. doi:10.1007/s000180050296. PMC   11146801 . PMID   10228554. S2CID   9448271.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ↑ "Santaris Pharma A/S: Another LNA-based RNA Inhibitor Enters Clinical Trials EZN3042". BioSpace. Retrieved 2024-05-12.
  11. 1 2 3 "Enzon Pharmaceuticals and Santaris Pharma Enter into Global Collaboration to Develop Novel Cancer Therapeutics; Alliance Strengthens Both Companies' Oncology Pipelines" (PDF). Enzon Pharmaceuticals. July 27, 2006. Retrieved 2024-05-12.
  12. 1 2 3 "Santaris advances a second drug from its cardiometabolic programme, SPC4955, into phase I trials to treat high cholesterol". test.pharmabiz.com. Retrieved 2024-05-12.
  13. ↑ Bejar, Nada; Tat, Trinh T.; Kiss, Daniel L. (May 2022). "RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases". Current Atherosclerosis Reports. 24 (5): 307–321. doi:10.1007/s11883-022-01007-9. ISSN   1523-3804. PMC   8975710 . PMID   35364795.
  14. 1 2 Chakraborty, Chiranjib; Sharma, Ashish Ranjan; Sharma, Garima; Doss, C. George Priya; Lee, Sang-Soo (2017-09-15). "Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine". Molecular Therapy - Nucleic Acids. 8: 132–143. doi:10.1016/j.omtn.2017.06.005. ISSN   2162-2531. PMC   5496203 . PMID   28918016.
  15. 1 2 3 Janssen, Harry L.A.; Reesink, Hendrik W.; Lawitz, Eric J.; Zeuzem, Stefan; Rodriguez-Torres, Maribel; Patel, Keyur; van der Meer, Adriaan J.; Patick, Amy K.; Chen, Alice; Zhou, Yi; Persson, Robert; King, Barney D.; Kauppinen, Sakari; Levin, Arthur A.; Hodges, Michael R. (2013-05-02). "Treatment of HCV Infection by Targeting MicroRNA". New England Journal of Medicine. 368 (18): 1685–1694. doi:10.1056/NEJMoa1209026. ISSN   0028-4793. PMID   23534542.
  16. ↑ "Santaris Pharma A/S advances miravirsen, the first microRNA-targeted drug to enter clinical trials, into Phase 2 to treat patients infected with Hepatitis C virus" (PDF). Globa Life Science Ventures. 2010-09-22. Retrieved 2024-05-12.
  17. 1 2 3 4 Otmani, Malin (2013-09-04). "Shire extends partnership with Santaris Pharma". Nordic Life Science – the leading Nordic life science news service. Retrieved 2024-05-12.
  18. ↑ Jarzemsky, Matt (2011-01-04). "Pfizer, Santaris Expand Collaboration Pact". Wall Street Journal. ISSN   0099-9660 . Retrieved 2022-03-05.
  19. 1 2 "Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance to Develop microRNA-Targeted Medicines for the Treatment of Cardiovascular Disease". www.prnewswire.com (Press release). Retrieved 2024-05-12.
  20. 1 2 A/S, Santaris Pharma. "Santaris Pharma A/S announce agreement with GlaxoSmithKline (GSK) to develop RNA-targeted medicines". www.prnewswire.co.uk. Retrieved 2024-05-12.
  21. ↑ "GSK, Santaris ink $700M development deal". Fierce Biotech. 2007.
  22. ↑ Writer, GEN Staff (2008-05-15). "Santaris Pharma Consortium Receives $9.33M to Develop RNA Drug Compounds". GEN - Genetic Engineering and Biotechnology News. Retrieved 2024-05-12.
  23. ↑ Joacim Elmén (2009). "LNA-mediated microRNA silencing in non-human primates". Nature. 452 (7189): 896–899. Bibcode:2008Natur.452..896E. doi:10.1038/nature06783. PMID   18368051. S2CID   4308734.
  24. ↑ Robert Lanford; Hildebrandt-Eriksen, ES; Petri, A; Persson, R; Lindow, M; Munk, ME; Kauppinen, S; Ørum, H (2010). "Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection". Science. 327 (5962): 198–201. Bibcode:2010Sci...327..198L. doi:10.1126/science.1178178. PMC   3436126 . PMID   19965718.
  25. ↑ Taylor, Nick (January 13, 2009). "Wyeth partners with Santaris on RNA development". Outsourcing Pharma.
  26. 1 2 "2010 RED HERRING TOP 100 EUROPE WINNERS". Red Herring. Retrieved 2024-05-12.
  27. ↑ Writer, GEN Staff (2011-02-28). "Santaris Pharma Licenses miRNA from MGH for Development in Cardiovascular Diseases". GEN - Genetic Engineering and Biotechnology News. Retrieved 2024-05-12.
  28. ↑ John Carrol (January 4, 2011). "Pfizer ups ante on Santaris RNA discovery deal with $614M pact". Fierce Biotech.
  29. ↑ "Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus". www.prnewswire.com (Press release). Retrieved 2024-05-12.
  30. ↑ "Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb for RNA-targeted medicines". www.prnewswire.com (Press release). Retrieved 2024-05-12.
  31. ↑ "RaNA Taps Santaris LNA Chemistry for RNA-Targeted Drug Development". GEN - Genetic Engineering and Biotechnology News. 2013-07-08. Retrieved 2024-05-12.
  32. ↑ "Roche to Acquire Santaris Pharma to Expand RNA Portfolio". Yahoo Finance. 2014-08-05. Archived from the original on 2015-07-08. Retrieved 2024-05-12.
  33. ↑ "Exiqon A/S completes litigation against Santaris Pharma a/s". GlobeNewswire News Room (Press release). 2011-10-07. Retrieved 2024-05-12.
  34. ↑ "Isis files patent infringement lawsuit against Santaris for antisense drugs". News Medical. September 26, 2011.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.